A wireless brain implant for treatment-resistant depression has received FDA clearance for human trials in the United States.
The FDA has granted Motif Neurotech approval to begin human trials of its Motif XCS System, a brain implant aimed at treatment‑resistant depression. The RESONATE study will follow patients for a year ...
Over the past 12 months, XCS has changed by 76.28%, with its 52-week range spanning from 20.44 to 37.79. What Is the Daily Trading Range for XCS? The daily trading range for XCS has fluctuated between ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
The FDA has authorized Motif Neurotech to begin clinical testing of its brain implant aimed at adults with treatment-resistant depression. The RESONATE study will assess safety, symptom improvement, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results